News
Tag: Financial & Investor News
-
Achieve Life Sciences Announces Presentations at Upcoming Investor Conferences
SEATTLE, Wash. and VANCOUVER, British Columbia, September 4, 2019 – – Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation, today announced that John Bencich, Chief Financial and Operating Officer, will present at two upcoming investor conferences. H.C. Wainwright 21st Annual Global…
-
Achieve Reports Financial Results for Second Quarter 2019 and Provides Cytisinicline Clinical Development Update
SEATTLE, Wash and VANCOUVER, British Columbia, August 8, 2019 — Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation, today provided an update on the cytisinicline clinical development program and announced second quarter 2019 financial results. Q2 2019 Highlights Reported positive results…
-
Achieve Life Sciences to Announce Second Quarter 2019 Financial Results and Host Conference Call and Webcast on August 8, 2019
SEATTLE, Wash. and VANCOUVER, British Columbia, July 30, 2019 — Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation, today announced that it will report its second quarter 2019 financial results on Thursday, August 8, 2019. Company management will host a conference…
-
Achieve Receives $4.2 Million from Exercise of Warrants
SEATTLE, Wash and VANCOUVER, British Columbia, June 3, 2019 — Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation, today announced that it entered into an agreement with a single investor to exercise outstanding warrants that will provide an aggregate of $4.2…
-
Achieve Reports Financial Results for First Quarter 2019 and Provides Cytisinicline Clinical Development Update
SEATTLE, Wash and VANCOUVER, British Columbia, May 15, 2019 — Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation, today provided an update on the cytisinicline clinical development program and announced first quarter 2019 financial results. ORCA-1 Trial Status Achieve’s 254-subject Phase…